ライフサイエンスコーパス: gallbladder cancer

1 es to identify miR-125b-5p down-regulated in gallbladder cancer.

2 olipid transporter genes in the pathology of gallbladder cancer.

3 hich mediates the function of miR-125b-5p in gallbladder cancer.

4 of Bcl2 is correlated with poor prognosis in gallbladder cancer.

5 select patients with incidentally discovered gallbladder cancer.

6 chemoradiotherapy for patients with resected gallbladder cancer.

7 , whereas VEGF variants were associated with gallbladder cancer.

8 zes advances in understanding the biology of gallbladder cancer.

9 herapeutic agents for the treatment of human gallbladder cancer.

10 ct of rapamycin as a potential treatment for gallbladder cancer.

11 aggressive wide resection for bile duct and gallbladder cancer.

12 l cholelithiasis, chronic cholecystitis, and gallbladder cancer.

13 fy common genetic susceptibility alleles for gallbladder cancer.

14 play a causative role in the development of gallbladder cancer.

15 considered in the differential diagnosis of gallbladder cancers.

16 Of 449 patients with gallbladder cancer, 207 cases (46%) were discovered inci

17 ary cancer (cholangiocarcinoma) (63 months), gallbladder cancer (47 months), metastatic colorectal ca

18 ield of laparoscopy was 48% in patients with gallbladder cancer (56% in those who did not undergo pre

19 Joint Committee on Cancer (AJCC) staging for gallbladder cancer (6th Edition) involved some major cha

20 lence of seropositivity was higher: 100% for gallbladder cancer, 97% of extrahepatic bile duct cancer

21 ntributed to the biochemical epidemiology of gallbladder cancer, a case-control study was undertaken

22 Records of 107 patients with gallbladder cancer admitted to a tertiary academic medic

23 f reoperation after an incidental finding of gallbladder cancer after cholecystectomy, and results of

24 as altered the presentation of patients with gallbladder cancer and determine whether radical resecti

25 ese imaging studies also serve to screen for gallbladder cancer and HCC.

26 ccuracy of laparoscopy between patients with gallbladder cancer and hilar cholangiocarcinoma.

27 Of these, three patients with gallbladder cancer and one patient with cholangiocarcino

28 patients with potentially resectable primary gallbladder cancer and patients with T2/T3 hilar cholang

29 IV stricture, biliary obstruction caused by gallbladder cancer and when only partial liver drainage

30 for re-resection for incidentally discovered gallbladder cancer appears to be between 4 and 8 weeks a

31 Although gallstones are recognized causes of gallbladder cancer, associations with other cancers of t

32 e-exploration after an incidental finding of gallbladder cancer at initial cholecystectomy.

33 ded for continued use in pancreatic head and gallbladder cancers but not in ampullary malignancies.

34 explored at a later point when found to have gallbladder cancer by subsequent pathology (n = 33).

35 The discovery cohort comprised 1042 gallbladder cancer cases and 1709 controls and the repli

36 ols and the replication cohort contained 428 gallbladder cancer cases and 420 controls.

37 n study (GWAS), we did a genome-wide scan of gallbladder cancer cases and hospital visitor controls,

38 125b-5p up-regulation promoted cell death in gallbladder cancer cells in the presence of cisplatin.

39 ockdown of miR-125b-5p reduced cell death in gallbladder cancer cells treated with cisplatin.

40 by data, an analysis of the 10,705 cases of gallbladder cancer collected between 1989 and 1996 in th

41 rget of rapamycin (mTOR; Ser(2448)) in human gallbladder cancer compared with normal gallbladder tiss

42 Although the OR for gallbladder cancer could not be calculated, the OR for t

43 using data from 4,180 patients with resected gallbladder cancer diagnosed from 1988 to 2003 from the

44 years with microscopically confirmed primary gallbladder cancer diagnosed or treated at Tata Memorial

45 In conclusion, cases with gallbladder cancer differed from controls with stones an

46 ausal association of gallbladder stones with gallbladder cancer (GBC) is not yet well established.

47 metastases on outcome after R0 resection of gallbladder cancer (GBCA).

48 Gallbladder cancer had been diagnosed preoperatively by

49 increased risk of cholangiocarcinoma (CCA), gallbladder cancer, hepatocellular carcinoma (HCC), and

50 d extended/radical cholecystectomy for T2/T3 gallbladder cancer; however, many tumors are discovered

51 ture (HR 2.082, P=0.008), obstruction due to gallbladder cancer (HR 31.029, P=0.012) and only partial

52 Preoperative predictors of incidental gallbladder cancer (iGBC) have been poorly defined despi

53 to have resulted in the earlier discovery of gallbladder cancer in some patients, resulting in increa

54 perihilar and distal cholangiocarcinomas and gallbladder cancers in Japanese patients.

55 so substantially influenced the treatment of gallbladder cancer; in other tumor types, results were i

56 to an open resection when identified to have gallbladder cancer intraoperatively (n = 6) and those wh

57 copic cholecystectomy and were found to have gallbladder cancer intraoperatively or following the ope

58 Unresected gallbladder cancer is a rapidly fatal disease.

59 e whether radical resection in patients with gallbladder cancer is beneficial.

60 The surgical management of gallbladder cancer is controversial.

61 Gallbladder cancer is highly lethal, with notable differ

62 ough adjuvant chemoradiotherapy for resected gallbladder cancer may improve survival for some patient

63 01, 100 patients with potentially resectable gallbladder cancer (n = 44) and hilar cholangiocarcinoma

64 ant epithelioid hemangioendothelioma: n = 1, gallbladder cancer: n = 1 or metastatic disease [colorec

65 sm has traditionally surrounded treatment of gallbladder cancer, particularly since the majority of c

66 s in the optimum management of patients with gallbladder cancer, particularly with respect to the pot

67 the net survival benefit of adjuvant RT for gallbladder cancer patients based on specific tumor and

68 tion as a new biomarker for the prognosis of gallbladder cancer patients.

69 t the Akt/mTOR pathway is activated in human gallbladder cancer, rapamycin and related drugs may be e

70 he benefit of adjuvant radiotherapy (RT) for gallbladder cancer remains controversial because most pu

71 Gallbladder cancer represents the most common malignancy

72 ement from the addition of adjuvant RT after gallbladder cancer resection.

73 eport of common genetic variation conferring gallbladder cancer risk at genome-wide significance.

74 ciated with substantial variation in risk of gallbladder cancer (sibling relative risk 3.15 [95% CI 1

75 review of 149 patients with the diagnosis of gallbladder cancer treated from 1985 to 1993 was perform

76 Gallbladder cancer was found incidentally in 53 patients

77 ith newly diagnosed histologically confirmed gallbladder cancer were compared with 264 controls with

78 ion (1987-2007) were analyzed; patients with gallbladder cancer were excluded.

79 Patients with resected gallbladder cancer were selected from the Surveillance,

80 esection for metastatic colorectal cancer or gallbladder cancer were usually considered cured.

81 l samples, miR-125b-5p was down-regulated in gallbladder cancer whereas Bcl2 was up-regulated and the

82 of 207 patients with incidentally discovered gallbladder cancer who underwent reoperation and had ava